THC prodrug ZYN001 enters Phase I testing

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) began a double-blind, placebo-controlled, dose-escalation Phase I trial to evaluate single and multiple doses of ZYN001 delivered by transdermal patches in up to 80 healthy volunteers. In the trial’s first part, single doses of ZYN001 delivered via a patch worn for 24 hours to 7 days will be evaluated in up to 48 healthy volunteers. In the second part, multiple patch applications of ZYN001 for 14 days will be evaluated in up to 32 healthy volunteers. The trial’s endpoints are safety and pharmacokinetics.

This half, Zynerba plans to start Phase II trials of ZYN001 in fibromyalgia and neuropathic pain...